Search

Aims: This meta-analysis aimed to evaluate the efficacy of sodium-glucose cotransporter-2 (SGLT-2) inhibitors in different types of heart failure (HF)., Methods: Randomized controlled trials (RCTs) comparing SGLT-2 inhibitors with placebo in patients with HF were searched in PubMed, the Cochrane Library database, and clinicaltrials.gov. A random-effects model was used for evidence synthesis. The primary endpoint was cardiac death., Results: We included 13 studies (12 RCTs). In patients with HF with preserved ejection fraction (HFpEF), SGLT-2 inhibitors reduced the composite endpoint of cardiac death or rehospitalization because of HF (HHF) (HR: 0.78, 95% CI: 0.70-0.87, I 2  = 0%, P < 0.001) and that of HHF (HR: 0.74; 95% CI: 0.64-0.85, I 2  = 0%, P < 0.001) but not that of cardiac death (HR: 1.01, 95% CI: 0.80-1.28, I 2  = 23.9%, P = 0.943). In patients with HF with reduced EF (HFrEF), SGLT-2 inhibitors reduced the composite endpoint of cardiac death or HHF (HR: 0.75, 95% CI: 0.69-0.82, I 2  = 0%, P < 0.001) and the individual endpoints of cardiac death (HR: 0.84, 95% CI: 0.75-0.95, I 2  = 0%, P = 0.007) and HHF (HR: 0.69, 95% CI: 0.62-0.77, I 2  = 0%, P < 0.001)., Conclusions: SGLT-2 inhibitors reduced the risk of cardiac death in patients with HFrEF but not in those with HFpEF., (Copyright © 2022 The Author(s). Published by Elsevier B.V. All rights reserved.)